Answers are grounded in this paper and cite their sources.
Abstract ID 131143 Poster Board 441 Benzalkonium chlorides (BACs) are widely used antimicrobials in a variety of consumer products and settings, including disinfectants, medical products, and the food-processing industry. Though initially recognized as safe, the FDA has called for additional safety data on BAC use in consumer products, including information on BAC biodistribution and metabolism. Notably, BAC exposure in rats led to their accumulation primarily in the kidney (42-fold higher than in blood); in contrast, accumulation did not occur in the liver, likely due to the efficient metabolism of BACs by hepatic cytochromes P450 (CYPs). Major BAC metabolites in humans and rodents consist of w- and w-1 hydroxy products, which can be further oxidized to COOH, diol, or ketone products. COOH-BAC metabolites then undergo β-oxidation as a central biotransformation pathway to form chain-shortened COOH-BAC products. While BACs were previously found to accumulate in the kidney, in vivo studies of BAC intrarenal distribution and local renal metabolism are lacking. Thus, this study employed UPLC-MS/MS and matrix-assisted laser desorption ionization (MALDI) imaging to probe BAC disposition in the kidneys of BAC-exposed mice. C57BL/6 male and female mice were treated with 120 mg/kg/day of d₇-C12 BAC or d₇-C16 BAC in a gel diet for one week. Kidney tissue was harvested, and LC-MS analysis showed that d₇-C16 BAC accumulated to a higher degree than d₇-C12 BAC in both males and females, averaging 18 times higher for males (concentrations of d₇-C12 BAC and d₇-C16 BAC ranged from 10-65 nM and 91-328 nM, respectively) and 29 times higher for females (concentrations of d₇-C12 BAC and d₇-C16 BAC ranged from 11-50 nM and 507-1551 nM, respectively). Male kidneys displayed d₇-C12 BAC and d₇-C16 BAC concentrations that were 20-fold and 60-fold higher, respectively, than average blood concentration. Likewise, female kidneys displayed d₇-C12 BAC and d₇-C16 BAC concentrations that were 10-fold and 144-fold higher, respectively, than average blood concentration. Quantitation of BAC in urine samples revealed very little to no parent BAC (<2.0 nM), whereas the hydroxy, COOH-BAC metabolites and β-oxidation products were observed readily; hydroxy and COOH-BAC metabolites were observed in the low nM range while β-oxidation products were present in excess of 100 nM. These results suggest that BAC accumulation in the kidneys is dependent on the alkyl chain length, and extensive metabolism is required to transform BACs into polar products for excretion in the urine. Complementing targeted analysis of BAC quantitation, MALDI imaging was used to resolve the regional distribution of BAC in the kidney. Preliminary images comparing a d₇-C16 BAC-treated kidney to a control kidney indicate that accumulation mostly occurs in the medulla region, suggesting regional kidney toxicity and potential kidney function impairment. In addition, differential lipid expression is demonstrated between untreated and treated tissues, such as increased expression of several phosphatidylcholines and phosphatidylglycerols. These altered lipids could serve as biomarkers of the kidney toxicity caused by BACs. To summarize, this study provides greater insight into BAC distribution and metabolism within the kidney.
No takes yet. Share an insight, caveat, or question.
Brzoska et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: